VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

18th February 2013 - News release

COGANE FAILS CLINICAL TRIALS FOR PARKINSON'S DISEASE

Phytopharm announced the results of the Phase II, randomised, double blind, placebo controlled, dose-ranging trial of Cogane in unmedicated patients with early-stage Parkinsonís Disease. Cogane was found to have no beneficial effects at all on Parkinson's Disease symptoms. For more information go to the News release

Cogane, which can be taken orally, readily crosses the blood-brain barrier and has been shown to stimulate the release of GDNF. GDNF can indirectly stimulate the formation of dopamine, the substance whose insufficiency causes Parkinson's Disease.  However, GDNF deficiency has never been shown to be the cause of Parkinson's Disease. Previous studies claiming efficacy for Cogane in Parkinson's Disease were only carried out in Macaque monkeys who did not actually have Parkinson's Disease. For a printable version of this article click here. For more news go to Parkinson's Disease News.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports

                                    

 

 
©2006-2013  Viartis
 
2015-08-25 02:55:59
 
[email protected]